Treatment option for patients Vincristine leurocristine with metabolic diseases, such as red-diabetes, multiple sclerosis, and obesity. Acknowledgements This study was sponsored by Boehringer Ingelheim International GmbH. Assistance in drafting and writing of Emma was Fulkes, PhD, of PAREXEL, which was acquired by Boehringer Ingelheim International GmbH, asked for these services. The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors, the full responsibility for s Mtliche content and editorial decisions, and have at all stages of development manuscript was involved, with the exception of Dr. Littlejohn, who died need during the preparation of the manuscript and was not able to endorse the final draft. Dr. Ting is the study statistician and provided data analysis. Mrs. Kobe is the monitor clinical trials. All authors have equally S to the preparation of the manuscript. The authors have again U no Entsch Endings associated with the development of the manuscript. used in CRPC, but none has been shown to have no effect on survival.4, 5 the FDA approval of the United States cabazitaxel and abiraterone sipuleucel T has an unmet need in CRPC offer effective Behandlungsm filled opportunities before and after chemotherapy with docetaxel. The introduction of these three drugs in clinical practice, paving the way for essential Changes in the treatment paradigm CRPC. The current and newly approved by the FDA Behandlungsm opportunities For CRPC will be covered in this article. Epidemiology of prostate cancer is the most hours Ufigsten diagnosed cancer in M Nnern in the United States, with a business Tzten 217 730 diagnosed in 2010.6 However, be expected to have only about 32 050 M Men die from prostate cancer in 2010 because Most patients in early stages of being diagnosed with survival rates approaching 100% 0.6 prostate cancer are associated, are usually made by sluggish growth in the early stages of the disease, but can metastasize sp ter to other sites such as eg . lymph nodes, liver, and most of the bones. Surgical resection, radiotherapy, and observation are all standard options of home Rztlichen included patients with localized disease.7 The choice between these options, many factors such as age, life expectancy, Gleason score, PSA, and tumor size E About 4% of all patients with prostate cancer will develop distant metastases disease.6 in this day and age, the survival rates five years for those patients with distant metastases concerning Gt 30% 0.6 The standard treatment primarily for patients with distant metastases diagnosed androgen deprivation because no curative treatment options are currently available. Castration failure is usually treated with hormonal side options, such as for each individual patient and based chemotherapy.7 The biology of the physiology of the prostate for prostate cancer for the presence of androgens and androgen receptors. AEs are unerl Ugly in the differentiation of cells of the Ridaforolimus prostate. Testes produce the M Nnchen 90 to 95% of the total percentage of the androgens in your body. Orchiectomy has shown that an effective treatment for prostate cancer by eliminating the production of androgens hormones.8, 9 Similarly, chemical castration through the use of androgen deprivation therapy also reduces testosterone levels below 50 ng / dl. W During my.
Related posts: